Oxybutynin

Adding on endotype-informed targeted combination therapies to oral appliance therapy helped reduce obstructive sleep apnea severity, according to results published in Annals of the American Thoracic Society.

PHILADELPHIA — Nonhormone therapy options for vasomotor symptoms are important considerations for women who are not good candidates for or may not want to initiate hormone therapy, according to a speaker.

Healio has compiled the most-read news in pulmonology posted in July.

A combination of atomoxetine and oxybutynin taken for 30 days lowered baseline obstructive sleep apnea severity, according to results published in Annals of the American Thoracic Society.